Immunogenicity of a peptide‐based anti‐IgE conjugate vaccine in non‐human primates

The anti‐human immunoglobulin E (IgE) monoclonal antibody, omalizumab (Xolair®, Genentech, South San Fransisco, CA), is effective in the treatment of poorly controlled moderate to severe allergic asthma and chronic idiopathic urticaria. It acts by specifically binding to the constant domain (Cϵ3) of...

Descripción completa

Detalles Bibliográficos
Autores principales: Weeratna, Risini D., Chikh, Ghania, Zhang, Lu, Fraser, James D., Thorn, Jennifer M., Merson, James R., McCluskie, Michael J., Champion, Brian R., Davis, Heather L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879460/
https://www.ncbi.nlm.nih.gov/pubmed/27957325
http://dx.doi.org/10.1002/iid3.98

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879460/
https://www.ncbi.nlm.nih.gov/pubmed/27957325
http://dx.doi.org/10.1002/iid3.98

Ejemplares similares